WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
UN food agency fears an escalation on the LebaneseKim Kardashian being booed by crowd at Tom Brady roast edited out of final Netflix cutHigh school students, frustrated by lack of climate education, press for changePennsylvania sees fewer mail ballots rejected for technicalities, a priority for election officialsAnother German politician is attacked as concerns rise over violence ahead of EU elections in JuneLithuania defends banning Russian and Belarusian observers from monitoring upcoming electionHouston mayor says police chief is out amid probe into thousands of dropped casesJames Argent showcases his toned arms following 14The secrets behind Kylie Minogue's ageFormer Las Vegas casino executive to be sentenced in bookmaking money laundering case